[3rd National Congress of Medical Oncology. Issues in Gynecologic Oncology. Naples, November 7, 2000].
Longo
F
F
Mansueto
G
G
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D005260:Female; D005500:Follow-Up Studies; D000077156:Gefitinib; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D009687:Nuclear Proteins; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000627:therapeutic use; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2; D011799:Quinazolines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015398:Signal Transduction / Q000187:drug effects; D019772:Topotecan / Q000627:therapeutic use
D000970:Antineoplastic Agents; D006133:Growth Substances; D009687:Nuclear Proteins; D009944:Organoplatinum Compounds; D011518:Proto-Oncogene Proteins; D011799:Quinazolines; D000077150:Oxaliplatin; D004815:Epidermal Growth Factor; D019772:Topotecan; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D017239:Paclitaxel; D002945:Cisplatin; D000077156:Gefitinib